Olga Payar @Olgapaval
Joined May 2021-
Tweets4K
-
Followers87
-
Following1K
-
Likes5K
New! Online now: IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibition dlvr.it/TSzBBY
New #JITC article: "Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity" jitc.bmj.com/content/14/6/e… @FulviaFerrazzi @H_Einsele
Ha salido la nueva guía 2026 del síndrome cardiovascular-renal-metabólico (CKM) y trae cosas interesantes. Os dejo lo que me parece más destacable, lo bueno y lo que no me cuadra tanto 🧵 @AHAScience @ACCinTouch @AmDiabetesAssn @ASNKidney Corazón, el riñón y el metabolismo no van por separado. Y es bueno ponerlo también sobre el papel. Lo que más me gusta: → Se estadifica el CKM (0 a 4), también en niños, para frenarlo a tiempo y hasta hacerlo retroceder. → La obesidad se trata como la raíz, no como un factor más de la lista. POR FIN. → iSGLT2 y GLP-1 como modificadores de enfermedad → Mirar siempre el riñón con FGe + cociente albúmina/creatinina. → Y meten los determinantes sociales en la ecuación. Sigo 👇
Excited to share out latest work, out this week in @NatureGenet . In this study, we using CRISPR screens to explore how sensing inflammatory cytokines exposes new tumor-intrinsic dependencies. @broadinstitute @MGBResearchNews nature.com/articles/s4158…
Can we revisit immunotherapy after progression on first-line chemoimmunotherapy in ES-SCLC? 🤔 In this real-world study (n=151), ICI rechallenge was associated with: ✅ Higher ORR (26% vs 11.8%) ✅ Better disease control (75% vs 47.1%) ✅ Longer PFS2 (4.0 vs 2.4 months) ✅ Longer OS (9.4 vs 6.2 months) While prospective validation is still needed, these data suggest that selected patients who initially benefited from immunotherapy may still derive benefit from an ICI-based approach beyond progression @OncoAlert @StephenVLiu @GlopesMd @weoncologists @ManuelDomine @christine_lovly @OncoReporte @MedwatchKate @LungCancerEu
New #JITC article: "Systemic pre-conditioning favors effector over exhausted CD8 T-cell subsets following Sup2-IL33 armored CAR T-cell therapy" jitc.bmj.com/content/14/6/e… @SundrudL @GeiselMed
THIS IS THE BEST PAPER OF 2026 SO FAR, A MONUMENTAL BREAKTHROUGH, A REVOLUTION IN THE FIELD OF INFLAMMATORY CONDITIONS: Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease | New England Journal of Medicine nejm.org/doi/10.1056/NE…
Tissue tension fosters macrophage-driven lipid peroxidation-induced DNA damage dlvr.it/TSzVNC
Important new paper on pulmonary carcinoids. not in the least, it changes the name to carcinoid/neuroendocrine tumor @IASLC Congratulations to @natasharekhtman from @MSKCancerCenter @AnjaRodenMD @IASLC @JTOonline @yasushi_yatabe jto.org/article/S1556-…
⭐️Online now Iron level and ferroptosis impair antitumor efficacy of CAR-T cells. by Dongrui Wang, Yongxian Hu, Pengxu Qian, He Huang & colleagues nature.com/articles/s4301…
Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways dlvr.it/TT0Hqm
New #JITC article: "IFN-γ PET imaging stratifies and predicts response to CD137 agonism in a syngeneic colorectal tumor model" jitc.bmj.com/content/14/6/e… @waynestate
Inflammatory cytokines induce new cancer dependencies @NatureGenet @broadinstitute @MangusoLab nature.com/articles/s4158…
⭐️Now online In a large cohort of patients with ICB-treated glioblastoma, Catherine J. Wu & colleagues show that baseline mesenchymal transcriptional state predicts therapy response, and transition to non-mesenchymal state results in acquired resistance. nature.com/articles/s4301…
Check out our latest review👏! We dive deep into how cDC1s orchestrate anti-tumor immunity through cross-presentation, immune networking, and spatial organization.
Ward, Kar, Balan, and Bhardwaj @BhardwajLab review how conventional type 1 #DendriticCells (cDC1s) coordinate antitumor immunity through cross-presentation, immune cell networking, and spatial organization in tumors. hubs.la/Q04kVmqr0 #CancerFocus #Immunotherapy
Bioelectric signaling as an emerging layer of macrophage communication dlvr.it/TSywZ6 #immunology
Spotlight @ImmunityCP Fibroblasts hold the key to TLS formation cell.com/immunity/fullt… cell.com/cancer-cell/fu… @Cancer_Cell
Machine Learning + Molecular Dynamics Reveal a Novel Flavonoid BCL-2 Inhibitor 🧬 Can AI discover the next-generation Venetoclax? A new study combined deep learning, virtual screening, molecular docking, and molecular dynamics simulations to identify novel flavonoid inhibitors targeting the anti-apoptotic protein BCL-2, a validated therapeutic target in chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma (MM). Key findings ✅ Built a deep neural network (DNN)-based QSAR model from 843 BCL-2 bioactivity records ✅ Screened a library of 4,857 flavonoids ✅ Predicted 83 compounds with potential BCL-2 inhibitory activity ✅ Molecular docking identified 10 top candidates ✅ 200-ns replicated molecular dynamics simulations revealed Comp-7 (3'-Prenylrubranine) as the most stable binder to BCL-2 Why Comp-7 stood out Although Venetoclax remained the strongest binder by docking score (-9.9 kcal/mol), Comp-7 demonstrated remarkable stability during long-timescale simulations: 🔹 RMSD converged within ~20 ns and remained below 0.2 nm 🔹 Stable protein dynamics with RMSF, SASA, and radius of gyration profiles comparable to Venetoclax 🔹 Maintained persistent hydrophobic interactions with key BCL-2 residues including ASP38, ARG42, TRP79, GLY80, ALA84, and LEU136 🔹 Displayed favorable drug-likeness characteristics with fewer medicinal chemistry rule violations than Venetoclax Why this matters Resistance to Venetoclax remains a major challenge in AML, CLL, and MM. This study highlights an emerging AI-driven drug discovery pipeline: 🧠 Deep learning → Virtual screening → Molecular docking → Molecular dynamics The identified hit, 3'-Prenylrubranine (Comp-7), is a relatively unexplored natural flavonoid with no substantial prior bioactivity literature, making it an intriguing scaffold for future BCL-2 inhibitor development. Important caveat This is an in silico discovery study. No cellular, animal, or clinical validation has yet been reported. Experimental confirmation will be required to determine whether Comp-7 truly induces apoptosis and overcomes Venetoclax resistance in hematologic malignancies. 📖 Reference Tondar A, Bepari AK, Reza HM, et al. Machine learning and molecular simulations reveal a prenyl plant flavonoid as a potent Bcl-2 inhibitor in cancer therapy In Silico Pharmacology (2026) DOI: 10.1007/s40203-026-00662-z #AIforDrugDiscovery #BCL2 #Venetoclax #AML #CLL #MultipleMyeloma #CancerResearch #MachineLearning #MolecularDynamics #DrugDiscovery #Flavonoids #ComputationalBiology #Bioinformatics #PrecisionOncology
Arterial stiffness is usually framed as a mechanical consequence of aging, blood pressure, and metabolic stress. But this new Aging Cell study suggests another layer: the immune repertoire itself may encode an early trajectory of vascular aging. Using peripheral TCRβ repertoire sequencing from 563 adults without overt cardiovascular disease, the authors linked immune repertoire architecture to brachial-ankle pulse wave velocity (baPWV), a clinical marker of arterial stiffness. The surprising finding: high PWV was not associated with the classic immunosenescence pattern of narrowed TCR diversity and dominant memory clone expansion. Instead, individuals with elevated arterial stiffness showed a paradoxical increase in TCRβ diversity, driven by broad remodeling of many low-frequency clonotypes. This is important because classical immune aging is often CD8+ memory/MAIT-biased, with repertoire contraction. Here, the PWV-associated signature was largely CD4+ T cell–driven, and it did not overlap with canonical age-related RFUs. The authors call this process “vascular immune remodeling.” Single-cell mapping suggested that these PWV-associated clonotypes preferentially localize to a naive-like / early-differentiation CD4+ compartment, but functionally they do not look “healthy naive.” Instead, they show features of: • chronic immune activation • interferon-α / interferon-γ response • proliferative restraint • impaired cell-cycle and metabolic programs • possible dysfunction rather than immune vigor The model proposed is elegant: vascular aging may have at least two partially dissociable immune trajectories. One is classical chronological immune aging, enriched in CD8+/MAIT-related repertoire shifts. The other is a CD4+ T cell-centered inflammatory remodeling state associated with subclinical arterial stiffening. Clinically, this matters because TCR features were predictive. A machine-learning model using PWV-associated repertoire functional units classified high PWV with AUC 0.817 in the internal validation set. The study remains cross-sectional, so causality is not proven. CD4+ remodeling may drive vascular stiffness, or vascular dysfunction may reshape immune tone. But either way, this work expands vascular aging beyond smooth muscle, collagen, elastin, and blood pressure. Key takeaway: arterial stiffness may carry an immune fingerprint—broad, low-frequency, dysfunctional CD4+ T cell remodeling—potentially opening a path toward immune-based vascular risk stratification and intervention. #Aging #VascularAging #Immunology #CD4Tcells #TCRrepertoire #CardiovascularDisease #Inflammaging #PrecisionMedicine
Trained Immunity Meets CAR-M: A New Playbook Against SCLC Small-cell lung cancer (SCLC) remains one of the deadliest solid tumors, with limited therapeutic options and a 5-year survival rate near 6%. While DLL3-targeted therapies such as ADCs, BiTEs, and CAR-T cells have shown promise, durable responses remain challenging due to poor tumor infiltration, immune suppression, and antigen escape. A new study introduces a compelling alternative: DLL3-targeted CAR macrophages (CAR-Ms) enhanced through β-glucan-induced trained immunity. Key Innovation Researchers engineered macrophages expressing a DLL3-specific CAR consisting of: DLL3 scFv CD8 hinge/transmembrane domain CD3ζ signaling domain Unlike CAR-T cells, macrophages naturally infiltrate solid tumors, phagocytose malignant cells, present antigens, and remodel the tumor microenvironment. Major Findings 🧬 Potent DLL3-specific killing ~60% killing of DLL3-high H146 SCLC cells in vitro Strong phagocytosis of DLL3-positive targets Near-complete destruction of DLL3+ tumor spheroids within 96 hours Minimal activity against DLL3-negative cells 🫁 Robust in vivo efficacy In both immunodeficient and immunocompetent mouse models: Significant tumor growth suppression Reduced tumor burden Increased tumor apoptosis No detectable systemic toxicity Importantly, CAR-Ms accumulated efficiently within tumors and persisted longer than control macrophages. Tumor Microenvironment Reprogramming DLL3-CAR-Ms transformed an immunologically "cold" SCLC microenvironment into a more inflamed state by: ↑ CD80+ M1 macrophages ↓ CD206+ M2 macrophages ↑ CXCL9/CXCL10/CXCL11 ↑ IL-2 and IFN-γ ↑ Antigen presentation programs These changes enhanced recruitment and activation of cytotoxic T cells. Synergy with PD-L1 Blockade Although anti-PD-L1 alone produced modest effects, combining checkpoint inhibition with DLL3-CAR-Ms generated significantly greater tumor control. This suggests macrophage-directed cellular therapy may sensitize otherwise resistant SCLC tumors to immune checkpoint blockade. The Most Exciting Part: Trained CAR-Ms The authors introduced a β-glucan training protocol: 24-hour β-glucan exposure 6-day resting period Tumor rechallenge The result was a macrophage population with durable innate immune memory. Compared with conventional CAR-Ms, trained CAR-Ms exhibited: ✅ Enhanced phagocytosis ✅ Increased cytotoxicity ✅ Sustained multi-round tumor killing ✅ Stronger inflammatory signaling ✅ Higher IFN-I responses ✅ Greater antitumor activity in vivo Mechanistic Insight: Mitochondria Drive Memory Multi-omics analysis revealed profound metabolic rewiring: Increased oxidative phosphorylation (OXPHOS) Elevated ATP production Increased mitochondrial mass Enhanced mitochondrial ROS (mtROS) Blocking mtROS with Mito-TEMPO markedly reduced: Tumor killing TNF-α production IL-1β production indicating that mitochondrial fitness is a central driver of trained CAR-M function. Why This Matters This work represents: 🔹 First DLL3-targeted CAR-macrophage therapy for SCLC 🔹 First demonstration of trained immunity engineering in CAR-Ms 🔹 Evidence that metabolic-epigenetic programming can enhance cellular immunotherapy durability 🔹 A potential strategy to overcome limitations of CAR-T therapy in solid tumors If validated clinically, trained DLL3-CAR-Ms could emerge as a next-generation platform combining innate immune memory, tumor penetration, and microenvironment remodeling for refractory neuroendocrine cancers. Reference Ying H et al. Trained immunity-primed DLL3-targeted CAR macrophages for the eradication of small cell lung cancer. Journal of Advanced Research (2026). DOI: 10.1016/j.jare.2026.05.047.
Nancy L @zlem29061448332
7 Followers 678 Following fairy lights & racing thoughts ✨ 100% follow back
오창명 @changmyung1981
513 Followers 890 Following M.D.,Ph.D. Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology.
Salim Jabbie @SalimJabbioess
2 Followers 75 Following
Nancy H @dHd2qGAOXDSsvSA
15 Followers 1K Following little bit feral, mostly floral 🌼 always follow back
Ying Cao @NeuralGrndState
538 Followers 425 Following My rubbish research: the core property of cancer cell is neural stemness, which determines pluripotency&tumorigenicity. EMT/MET/EndMT are groundless 'concepts'
Medical Sciences @medsci_MDPI
976 Followers 893 Following Medical Sciences is an international #openaccess journal publishing advances in basic, translational & clinical medical research. By @MDPIopenaccess.
Iñaqui Jiménez-Loyg... @InaquiConQ
428 Followers 677 Following Sometimes Juan Ignacio. Postdoctoral fellow at @CNIOStopCancer @Gsabiolab. Investigating why our cells eat themselves. 🌱. 🏳️🌈. 🍉. (he/him)
Yang Zhao @YangZhao102
163 Followers 198 Following T cell engineering & cytokine signaling in the Garcia lab|Postdoc @Stanford_MCP |CRI fellow @CancerResearch | PhD @EPFL
Center for Epigenomic... @CEpigenomics
2K Followers 536 Following Est. @UC San Diego to answer human health and science questions through epigenomic research, tech & partnerships. https://t.co/MC9Q0wHNiA (Director: Bing Ren)
Sara Elizabeth Siegle... @sesiegler
4K Followers 5K Following Personal account of the CEO/Owner of @SES_HQ. Co- Chair. Ceiling smasher, recovering equestrian, former whistleblower, pickleballer, & pemphigus patient.
Nelumbo nucifera @punkkauz
52 Followers 112 Following Longevity sci enthusiast. Bioinformatician.... 'What is your destiny?You are not just an individual but you represent all lives. Where are you taking them?'
Jeremy Cliffe @Jeremy_L_cliffe
37 Followers 329 Following Financing, Business, and personal needs. Expert in mortgages, business loans, and financial growth strategies.
Miner Lab @miner_lab
2K Followers 2K Following Mechanisms & therapies for rare rheumatic diseases. Chair, Gene Therapy and Vaccines (GTV) Graduate Program @CAMBUPenn @UPenn_I3H @pennmedicine @rvcl_research
Jon Hershon @jonathanhershon
6K Followers 5K Following VP Clinical AI @doximity, prev CEO @pathwaymedical (acq. Doximity)
Dmitry Kovalchuk @DmitryKovalchuk
2K Followers 967 Following Stocks, private equity, economics, and international politics. Personal views only. P.S. Don't follow my investment ideas, my investments lose money regularly.
David Sinclair @davidasinclair0
43 Followers 373 Following Professor @Harvard researching why we age & how to reverse it. Author & host of Lifespan. Mission: Extend healthy life for all.Views are entirely his own ✌🙏
Klebanoff_Lab @KlebanoffLab
3K Followers 2K Following A translational research lab @MSKCancerCenter focused on the immunobiology and therapeutic potential of genetically engineered #Tcells and #TCRs. Est.2016 @NYC.
Upasana DasAdhikari @UpasanaDA
584 Followers 994 Following NIDDK K99/R00 fellow-Mucosal Immunology_Immunometabolism-specializing in organoids modelling of human _KwonLab@Ragon Institute of MGH, Harvard& MIT
Frank George @frank_george927
68 Followers 743 Following God❤️family ❤️fitness Support & athletes 🏃♀️ Gym freak🏋️♀️ Active & devoted 😊 Animal lover🐕🦺music lover, single dad a beautiful girl 👨👧
Razelle Kurzrock, MD @Dr_R_Kurzrock
9K Followers 7K Following Momx7 (4 children; 3 dogs); wife; Director, Center, Precision Oncology/Rare Cancers; CMO WIN; physician, not provider; CureMatch (cofounder); opinions mine
Delvys Rodriguez Abre... @delvysra
1K Followers 619 Following A lung cancer medical oncologist. Engaged with patients hope. Father. Founder @FCCPulmon
Yoshihisa Okazaki @XX62
2K Followers 3K Following 消化器内科医・モナドロジスト・医学博士・数学修士・岡崎能久 MD・PhD・MS 東北大学医学部(1-2年)大阪大学医学部3年次編入卒 千葉大学数学科・大阪大学大学院修士(数学)近畿大学病院・羽曳野医療センターetc勤務 岡山県金光学園中高卒 広島県福山市鞆町(岡崎雄志郎宅) 中高数学専修免許 医師免許(2001)
Stevenlucas @Stevenluca37105
35 Followers 1K Following I,m always smiling and looking the brightest side of the earth
Navonil DS @Navonilde
382 Followers 699 Following (Pronouns He/Him). DAD/Husband/Scientist @ProstateCancer @CancerGenomics @Biomarker_Research @Mountain_Lover @DNA repair @Signature 'tweet are mine'
Pat Adams @PathologyPat
2K Followers 5K Following Product Development New England, Naveris, NavDx, minimal residual disease monitoring in head and neck cancer
Frontiers in Bioscien... @Landmark_IMR
562 Followers 920 Following Open access journal for cellular and molecular biology, Indexed in SCIE, PubMed, Scopus and more. COPE member IF: 3.1 💌 [email protected]
Jitendra K Meena @jitendrakmeena
120 Followers 360 Following Cancer researcher in RNA biology @BCM, Houston | interested in developing therapeutics based on RNA degradation
Biologyto @thebiologyto
28 Followers 222 Following Welcome to house of biology 🧫 A breathing ecosystem of knowledge 🧪 Your exploration of the extraordinary begins here 🌻 Join us and live biology 🧬
Göktuğ @GuvercinGoktug
1K Followers 488 Following Ex @AstraZeneca 💊🧫| MSc @TU_Muenchen & @imperialcollege 👨🏼💻| Working Area: Computer Vision, Language Modeling, Drug Discovery
ROS1 Cancer @ROS1CancerSpain
143 Followers 1K Following Because everyone deserves the best diagnosis and the best treatment for their disease. #ROS1 advocate. #ROS1agnostic
Neuroendocrine Cancer... @ncukcharity
5K Followers 5K Following Supporting the #Neuroendocrine Cancer community, incl diagnosis, access to best treatment & care - and stimulating research. Helpline 0800 434 6476
NET Cancer Day @netcancerday
6K Followers 3K Following Worldwide NET Cancer Awareness Day is an awareness-raising event coordinated by INCA, the International Neuroendocrine Cancer Alliance.
Jessica Duarte @JessDGDuarte
1K Followers 2K Following Laboratory Head @monashSTM working on B cell tumour immunology, tertiary lymphoid structures, and protein microarrays
Lingshuang Chen @LCbio
21 Followers 65 Following 📖PhD student @Sutherland_Lab @WEHI_research 👩🔬Bioscientist / small cell lung cancer / single cell technology | Views are my own
Elias Orouji @orouji
2K Followers 2K Following Epigenomics Lead at Princess Margaret Cancer Centre @pmcancercentre @uhn | University of Texas MD Anderson Cancer Center @MDAndersonNews | DKFZ @dkfz alumnus
Isabel Puig Borreil @IPuigBorreil
729 Followers 840 Following Senior Investigator at @VHIO. Co-founder of @OniriaTx. Investigating non-genetic cancer persistence. @ipuigborreil.bsky.social
TIAN TIAN @vicenttianfr
580 Followers 833 Following M.D. Ph.D. Interested in pancreaticobiliary malignancies. Hospital Clínic Foundation for Biomedical Research (FCRB) IDIBAPS
Enric Barba Ibáñez @EnricBarba
2K Followers 4K Following Dr. Ingeniero de telecomunicación. Ph.D. Telecommunications Engineering. Melanoma Patient Advocate. @MelanomaE @MNPEurope @myESMO
OncoDaily @oncodaily
9K Followers 8K Following Where the global cancer community meets - daily news, trial breakdowns. KOL interviews, live from major cancer congresses OncoDaily - The Voice of Oncology
Gabriel Espinosa Carr... @Gabriel198685
18 Followers 39 Following Cancer Immunologist passionate about the development of new immunotherapy
Jessica Berg @ber19117
10 Followers 133 Following She/Her/Ella. | BS in exercise | your fave | ❤️🧡💛💚💜💙
Hind Rafei @HindRafei
3K Followers 4K Following Physician-scientist at MD Anderson Cancer Center investigating cellular immunotherapy for cancer with a focus on metabolic-epigenetic crosstalk in the TME.
The Shields Lab @TheShieldsLab
139 Followers 120 Following Focused on #SCLC | PI @drshieldsmd | #liquidbiopsy #methylation #subtypes #drugscreen | overcome #resistance | bench to bedside | IU Simon Comprehensive Cancer
SmallCellSMASHERS @SclcSMASHERS
358 Followers 250 Following Advocacy group/voice of patients with #SCLC & loved ones. Mission: #community - awareness for #research - end #stigma - spread #hope @drshieldsmd @lungevity
Tomoaki Kinjo @tkinjo8
5K Followers 6K Following Postdoc in Kuhlman lab @UNC_BCBP Computational protein design for cancer immunotherapy
Zach Walsh @zwalsh96
200 Followers 407 Following @columbiamed md/phd candidate | t cell engineering and immunogenetics @ izar lab | nci f30 fellow
Elicio Therapeutics @ElicioTx
420 Followers 30 Following Elicio (Nasdaq: $ELTX) is advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers.
Maria Robles @RBioceutics
3K Followers 409 Following President & CEO of Robles BioCeutics | Developers of Advanced Senolytic & Regenerative Cosmeceuticals
Satchin Panda @SatchinPanda
53K Followers 95 Following Professor at Salk Institute. Author of the books, The Circadian Code and The Circadian Diabetes Code. https://t.co/GUiq4LWKUj
Yago Garitaonaindía @YGaritaonaindia
314 Followers 595 Following Translational research fellow. TIL group. CCIT-DK, Copenhagen (Denmark) | JNCI journals Social Media Editor #MedOnc
Matt Schwartz @matt_is_nice
2K Followers 3K Following CEO/founder of Virgo. Building frontier AI to solve gut-mediated diseases like colorectal cancer, pancreatic cancer, IBD, and more
David Lagares, PhD, M... @david_lagares
712 Followers 527 Following Scientist-Entrepreneur | CEO & Founder - Zenon Biotech | Co-Founder - Mediar Therapeutics | Lagares Lab - Cancer, Tissue Regeneration and Fibrosis
Charlotte Kuperwasser... @KUPERWASSERLAB
2K Followers 207 Following Professor @TuftsMedSchool, Co-Founder @Naveris_inc. Dedicated to understanding the biological, molecular, and genetic underpinnings of cancer & prevention.
Garry P. Nolan @GarryPNolan
127K Followers 123 Following Be better than before. Cancer Bio, Immunology, Bio-Computation, 🏳️🌈, UAP/SETI. Negative posters blocked w/o pause.
Aaron Newman Lab @AaronNewmanLab
1K Followers 271 Following Computational biology, cancer genomics, & stem cell bioinformatics lab @Stanford @czbiohub
오창명 @changmyung1981
513 Followers 890 Following M.D.,Ph.D. Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology.
Molecular Cancer Ther... @MCT_AACR
2K Followers 148 Following The go-to journal for transitioning experimental therapies developed at the bench into clinical investigation, from preclinical study to phase I trials.
Paperbirds_Oncology @PaperbirdsO
885 Followers 121 Following Paperbirds is an initiative committed to deliver unbiased daily literature updates and information about new clinical trials to health care professionals
Myogenesis Discussion... @MyogenesisGroup
1K Followers 195 Following A virtual discussion group on skeletal/smooth/cardiac muscle funded by @MbD_UofT, @UofT, organized by @RokMatthew and @xu_bellaxixi
Melody Zeng @melodyzeng
831 Followers 295 Following Associate Professor @WeillCornell @Cornell. We study the interface between the immune system and gut microbiome in early development. Instagram @zenglaboratory
CA: A Cancer Journal ... @CACancerJournal
11K Followers 2K Following As the flagship journal of the American Cancer Society, CA publishes the latest cancer statistics, ACS guidelines, and reviews on the current state of cancer.
Zihai Li, MD, PhD @Zihai
3K Followers 710 Following Founding Director, Pelotonia Institute for Immuno-Oncology (@OhioStatePIIO) • Deputy Director of @OSUCCC_James for Translational Research • Views My Own
Adam Rubin @adamjrubin
256 Followers 268 Following Helen Hay Whitney Foundation postdoctoral fellow with Alex Shalek and Aviv Regev at the Broad Institute
Katie Galloway @GallowayLabMIT
8K Followers 2K Following Assistant Prof @MITChemE ; mom^4 + wife; enjoys building cell-fate circuits, exploring dna topology, reprogramming the living world, and soccer; soli gloria deo
Prof. Nikolai Slavov @slavov_n
40K Followers 266 Following Mentor, scientist & engineer. Director of @ParallelSqTech. Having fun in @SlavovLab with single-cell proteomics & ribosomes. Organizer of @SCP_meeting
Amy Fan @amycfanphd
1K Followers 1K Following Postdoc with @MaxKrummel | @stanfordimmuno PhD with @majetilab | #dancer, #educator, #advocate | she/her | Formerly @MIT & @broadinstitute
Sandra Ortiz-Cuaran @SandraOrtizCua1
92 Followers 473 Following Translational lung cancer scientist at Cancer Research Center of Lyon / Centre Leon Berard. Lead, BOLERO Consortium on #BRAF-mutant NSCLC: https://t.co/Iyxs0Q
Brad Schoenfeld, PhD @BradSchoenfeld
98K Followers 49 Following Researcher/educator on muscle building and fat loss. Author: "The MAX Muscle Plan" & "Science and Development of Muscle Hypertrophy." https://t.co/ye3quvBlEy
Gustavo Duque @DrGustavoDuque
4K Followers 2K Following A geriatrician and #geroscience researcher with a particular interest in the mechanisms and treatment of #osteoporosis, #sarcopenia & #frailty in older persons.
Matthew S. Alexander @Matt_Muscle_Guy
6K Followers 4K Following Geneticist, Skeletal Muscle, Drug development, Gene therapies. Non-coding RNA, and Zebrafish Aficionado. All tweets are my own. Instagram @thealexanderlab
若林秀隆 (Hidetak... @HideWakabayashi
15K Followers 7K Following MD, PhD, Rehabilitation doctor (TWMU professor), rehabilitation nutrition, sarcopenia, cachexia, dysphagia 東京女子医科大学リハ科教授、リハ栄養、本アカウントの投稿は個人の意見であり、所属組織の代表ではありません
Adam Sharples Ph.D -B... @DrAdamPSharples
7K Followers 293 Following Our Group 1st Demonstrated that Human Muscle possesses an Epigenetic Memory of Exercise -Our DNA remembers exercise! | ExProRugby | Judo
Christoph Burch @ChristophBurch
16K Followers 134 Following Physio interested in Exercise Therapy | Progressive Relaxation | Mindfulness | CBT in Physio | Embodied Cognition | Running | Fly Fishing | tweeting≠endorsement
Craig A. Goodman @CraigAGoodman1
4K Followers 512 Following Senior Scientist that investigates the molecular mechanisms that regulate skeletal muscle mass and function in health and in various disease states
Carla Prado, PhD, RD,... @DrCarlaPrado
4K Followers 675 Following Distinguished Professor | Nutrition Ambassador | Tier 1 Canada Research Chair | @CAHS_ACSS | @Top40_40 | @WXN 🇨🇦 Most Powerful Women. Own views 🇨🇦 🇧🇷
Stuart Phillips (he/h... @mackinprof
58K Followers 5K Following Distinguished Univ Professor, tier 1 @CRC_CRC, @McMasterU; opinions mine. https://t.co/9FZmrkm1K4. https://t.co/6w6NWxajVX recovering biohacker
Kevin Murach @KevinMurachPhD
3K Followers 1K Following Studying muscle in the Ozark mountains - M3R Lab. Bourbon aficionado. Amateur watch builder. Average exerciser. My wife says I’m a “six wing five”.
Journal of Cachexia, ... @JCSM_cachexia
2K Followers 140 Following JCSM is a peer-reviewed journal publishing research related to body composition, muscle loss during normal lifespan & as part of chronic disease. @SCWDNews
Dr Rishabh Jain @DrRishabhOnco
7K Followers 3K Following 🩺 DM Medical Oncologist, AIIMS Delhi 🌍 . Let’s keep oncology interesting !
Lori Shemek, PhD @LoriShemek
169K Followers 70K Following Health Expert * 4X Bestselling Author * aka “The Inflammation Terminator” * Podcast Host* Fox News * CBS The Doctors TV * Huff Post Top Health Expert* #MAHA
Hypersensitivity Pneu... @RespiratoryHP
17 Followers 0 Following Collaborating with health care professionals to innovate diagnosis and management of Hypersensitivity Pneumonitis
Medical Sciences @medsci_MDPI
976 Followers 893 Following Medical Sciences is an international #openaccess journal publishing advances in basic, translational & clinical medical research. By @MDPIopenaccess.
Lucas Sullivan @LucasBSullivan
2K Followers 2K Following Associate professor @fredhutch & @UW. Studying metabolic constraints of cancer cell proliferation. On a mote of dust suspended in a sunbeam.
Nature ダイジェ�... @NatureDigest
36K Followers 1K Following 科学雑誌Nature(ネイチャー)のニュースには研究のヒントが満載!それを日本語で読める月刊誌『Nature ダイジェスト』です。科学の視点で社会動向を伝え、地球規模の課題を炙り出します。オンライン版(8470円/年)は全バックナンバー(https://t.co/o1UoS6vsiA、PDF含む)にアクセス可
Penn Engineering @PennEngineers
11K Followers 554 Following The official X page for the University of Pennsylvania's School of Engineering and Applied Science. #InventingtheFuture #PennEngineering
Anktiva @anktivaofficial
707 Followers 1 Following Anktiva® (nogapendekin alfa inbakicept-pmln) PI: https://t.co/IPWL2902my Community Guidelines: https://t.co/CoqpEsahwe
Dr. Thomas Ichim @exosome
37K Followers 38K Following President and Chief Scientific Officer of Immorta Bio Vitalist https://t.co/fbVtWsFQw4 503 patents 4 Exits https://t.co/GHnwkq884f
Sean @S_Gallagher23
2K Followers 1K Following Building better biotechs 🧬 | ATMP clinical regulatory strategist | MS Phys/Pharma @UF · BA Neuro @VanderbiltU | Miami 🌴 | Opinions are my own
Mario Balsa @MarioBalsaMD
2K Followers 692 Following Galleguiño 🌊 | Med Onc resident @ICO_oncologia | Skin cancer, IO & cell therapy 🎯 | 2025 Rotation Research @UTMDAnderson 🇺🇸 | @OncoAlert team💥 | Pianist 🎹
Diego A. Díaz-Garcí... @diegoadiazg
2K Followers 1K Following Medical Oncologist • Thoracic Oncology @incanMX alum | #CánCare • Hosp. Angeles Andares | Views my own
Bo Wang @BoWang87
30K Followers 3K Following Prof @UofT | Building first Virtual Cell @Xaira_Thera | Chief AI Scientist @UHN | AI & Bio & Healthcare | Inventor of scGPT, MedSAM, BioReason | Opinions my own



















